Filtered By:
Condition: Epilepsy
Therapy: Chemotherapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 17 results found since Jan 2013.

Role of TREK-1 in Health and Disease, Focus on the Central Nervous System
Conclusion and Perspectives Since their cloning 20 years ago, the physiological importance of TREK-1 channels has continued to grow (Figure 3). Today, TREK-1 channels have been shown to be important and their presence is essential in a number of physiopathological processes. Their involvement in these different processes demonstrate the necessity to design pharmacological modulators, activators or inhibitors, of these channels to correct any TREK-1-related dysfunctions. Despites a number of studies and many molecule screenings, only few putative new drugs were identified. The activators belonging to the ML and BL series ...
Source: Frontiers in Pharmacology - April 10, 2019 Category: Drugs & Pharmacology Source Type: research

The New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications.
Authors: Hanaya R, Arita K Abstract The administration of antiepileptic drugs (AEDs) is the first treatment of epilepsy, one of the most common neurological diseases. Therapeutic guidelines include newer AEDs as front-line drugs; monotherapy with new AEDs is delivered in Japan. While about 70% of patients obtain good seizure control by taking one to three AEDs, about 60% experience adverse effects and 33% have to change drugs. Compared to traditional AEDs, the prolonged administration of new AEDs elicits fewer adverse effects and fewer drug interactions and their teratogenicity may be lower. These characteristics i...
Source: Neurologia Medico-Chirurgica - March 6, 2016 Category: Neurosurgery Tags: Neurol Med Chir (Tokyo) Source Type: research

Hacking The Nervous System
(Photo: © Job Boot) One nerve connects your vital organs, sensing and shaping your health. If we learn to control it, the future of medicine will be electric.When Maria Vrind, a former gymnast from Volendam in the Netherlands, found that the only way she could put her socks on in the morning was to lie on her back with her feet in the air, she had to accept that things had reached a crisis point. “I had become so stiff I couldn’t stand up,” she says. “It was a great shock because I’m such an active person.”It was 1993. Vrind was in her late 40s and working two jobs, athletics coach and a carer for disabled ...
Source: Science - The Huffington Post - May 30, 2015 Category: Science Source Type: news

Epilepsy and Cancer: Ancient Problem in a Top Mortality Illness (P3.313)
CONCLUSIONS: Seizures in patients with cancer is a frequent comorbid condition with a high mortality rate, further studies are required to study the efficacy and security of AED and other forms of treatment.Study Supported by: NoneDisclosure: Dr. Cacho Diaz has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Cacho Diaz, B. Tags: Neurologic Complications of Cancer Source Type: research

Temozolomide in low-grade gliomas: living longer and better
Low-grade gliomas (LGGs) account for about a third of gliomas overall and 15% of all primary brain tumours. In adults, the majority of LGGs are WHO Grade II astrocytomas and oligodendrogliomas, which differ in molecular fingerprints and median survival, but share a propensity to malignant transformation after a number of years. Up to 90% of LGGs present with seizures and epilepsy may be the only symptom for many years, significantly impairing quality of life and impacting on social and professional functioning.1 In about 50% of cases, the epilepsy is refractory to antiepileptic drugs (AEDs) with a quarter of patients requi...
Source: Journal of Neurology, Neurosurgery and Psychiatry - March 13, 2015 Category: Neurosurgery Authors: Rees, J. Tags: Immunology (including allergy), Epilepsy and seizures, Neurooncology, Stroke, CNS cancer, Radiology, Surgical oncology Editorial commentaries Source Type: research

Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide
Conclusions TMZ may contribute to an important reduction in seizure frequency in patients with LGG. Seizure reduction following TMZ treatment has prognostic significance and may serve as an important clinical outcome measure in patients with LGG.
Source: Journal of Neurology, Neurosurgery and Psychiatry - March 13, 2015 Category: Neurosurgery Authors: Koekkoek, J. A. F., Dirven, L., Heimans, J. J., Postma, T. J., Vos, M. J., Reijneveld, J. C., Taphoorn, M. J. B. Tags: Epilepsy and seizures, Neurooncology, Stroke, CNS cancer Neuro-oncology Source Type: research

Clinical Reasoning: A 68-year-old man with a history of lung cancer presenting with right-sided weakness and aphasia
A 68-year-old man with paroxysmal atrial fibrillation on warfarin, left subclavian thrombosis treated with carotid-subclavian bypass, and lung adenocarcinoma treated with pneumonectomy, chemotherapy, and prophylactic cranial irradiation and in remission since 1987 was admitted to our neurocritical care unit with acute onset of right-sided weakness, expressive aphasia, and lethargy. On admission his temperature was 101.7°F, and initial blood pressure was 140/60 mm Hg. There was no nuchal rigidity. He was alert and mute with impaired comprehension. He had left gaze preference. Vision was impaired in the right field. Ther...
Source: Neurology - October 5, 2015 Category: Neurology Authors: Gupta, A., Etherton, M. R., McKee, K., Baker, J. M., Izzy, S., Feske, S. K. Tags: All Cerebrovascular disease/Stroke, Radiation therapy-tumor, All Epilepsy/Seizures RESIDENT AND FELLOW SECTION Source Type: research

Neurocognitive Deficits and Neurocognitive Rehabilitation in Adult Brain Tumors
Opinion statement Neurocognitive deficits are common with brain tumors. If assessed at presentation using detailed neurocognitive tests, problems are detected in 80 % of cases. Neurocognition may be affected by the tumor, its treatment, associated medication, mood, fatigue, and insomnia. Interpretation of neurocognitive problems should be considered in the context of these factors. Early post-operative neurocognitive rehabilitation for brain tumor patients will produce rehabilitation outcomes (e.g., quality of life, improved physical function, subjective neurocognition) equivalent to stroke, multiple sclerosis, ...
Source: Current Treatment Options in Neurology - April 4, 2016 Category: Neurology Source Type: research

P08.46 Rechallenge with bevacizumab in a long-term survivor with glioblastoma
The prognosis of patients with glioblastoma multiforme (GBM, WHO grade IV), the most common primary brain tumor in adults, is generally poor with median survival of less than one year in untreated patients and approximately 15 months following standard of care therapy. However, 10 % survival at 5 years was observed in a randomized phase III study. At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3–4 month prolongation of progression-free survival (PFS) without improving overall survival (OS...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Koeppen, S., Hense, J. Tags: P08 Glioblastom and Anaplastic gliomas Source Type: research

Therapeutic dormancy to delay postsurgical glioma recurrence: the past, present and promise of focal hypothermia
AbstractSurgery precedes both radiotherapy and chemotherapy as the first-line therapy for glioma. However, despite multimodal treatment, most glioma patients die from local recurrence in the resection margin. Glioma surgery is inherently lesional, and the response of brain tissue to surgery includes hemostasis, angiogenesis, reactive gliosis and inflammation. Unfortunately, these processes are also associated with tumorigenic side-effects. An increasing amount of evidence indicates that the response to a surgery-related brain injury is hijacked by residual glioma cells and participates in the local regeneration of tumor ti...
Source: Journal of Neuro-Oncology - May 17, 2017 Category: Cancer & Oncology Source Type: research

Valproic acid and epilepsy: from molecular mechanisms to clinical evidences.
Abstract After more than a century from its discovery, valproic acid (VPA) still represents one of the most efficient antiepileptic drugs (AEDs). Pre and post-synaptic effects of VPA depend on a very broad spectrum of actions, including the regulation of ionic currents and the facilitation of GABAergic over glutamatergic transmission. As a result, VPA indirectly modulates neurotransmitter release and strengthens the threshold for seizure activity. However, even though participating to the anticonvulsant action, such mechanisms seem to have minor impact on epileptogenesis. Nonetheless, VPA has been reported to exer...
Source: Epilepsy Curr - December 27, 2018 Category: Neurology Authors: Romoli M, Mazzocchetti P, D'Alonzo R, Siliquini S, Rinaldi VE, Verrotti A, Calabresi P, Costa C Tags: Curr Neuropharmacol Source Type: research

An Agathokakological tale of ∆9 -THC: Exploration of Possible Biological Targets.
Abstract ∆ 9 -Tetrahydrocannabinol (∆9 -THC), the active phytocannabinoid in cannabis, is virtually an adjunct to the endogenous endocannabinoid signaling system. By interacting with G-protein-coupled receptors CB1 and CB2, ∆9 -THC affects peripheral and central circulation by lowering sympathetic activity, altering gene expression, cell proliferation, and differentiation, decreasing leukocyte migration, modulating neurotransmitter release thereby modulating cardiovascular functioning, tumorigenesis, immune responses, behavioral and locomotory activities respectively. ∆ 9 -THC is effective in suppressing c...
Source: Current Drug Targets - September 30, 2020 Category: Drugs & Pharmacology Authors: Mathew B, Harilal S, Musa A, Kumar R, Parambi DGT, Jose J, Uddin MS, Shah MA, Behl T, Unnikrishnan MK Tags: Curr Drug Targets Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news